Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Assets (2016 - 2025)

Historic Assets for Haemonetics (HAE) over the last 16 years, with Q4 2025 value amounting to $2.5 billion.

  • Haemonetics' Assets fell 159.52% to $2.5 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $2.5 billion, marking a year-over-year decrease of 159.52%. This contributed to the annual value of $2.5 billion for FY2025, which is 1163.04% up from last year.
  • Per Haemonetics' latest filing, its Assets stood at $2.5 billion for Q4 2025, which was down 159.52% from $2.4 billion recorded in Q3 2025.
  • In the past 5 years, Haemonetics' Assets ranged from a high of $2.5 billion in Q2 2024 and a low of $1.8 billion during Q3 2021
  • Moreover, its 5-year median value for Assets was $2.0 billion (2023), whereas its average is $2.1 billion.
  • Its Assets has fluctuated over the past 5 years, first soared by 4362.79% in 2021, then crashed by 328.95% in 2025.
  • Over the past 5 years, Haemonetics' Assets (Quarter) stood at $1.8 billion in 2021, then increased by 4.25% to $1.9 billion in 2022, then increased by 17.16% to $2.2 billion in 2023, then increased by 15.04% to $2.5 billion in 2024, then dropped by 1.6% to $2.5 billion in 2025.
  • Its Assets stands at $2.5 billion for Q4 2025, versus $2.4 billion for Q3 2025 and $2.5 billion for Q2 2025.